Development
Recursion Pharmaceuticals, Inc.
RXRX
$5.49
$0.9220.13%
NASDAQ
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
P/E (TTM)
--
EPS (TTM)
| 12/31/2023 | 09/30/2023 | 06/30/2023 | 03/31/2023 | 12/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 44.58M | 47.36M | 49.99M | 46.64M | 39.84M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 44.58M | 47.36M | 49.99M | 46.64M | 39.84M |
| Cost of Revenue | 42.59M | 103.58M | 78.94M | 67.16M | 48.28M |
| Gross Profit | 1.99M | -56.22M | -28.95M | -20.52M | -8.43M |
| SG&A Expenses | 110.84M | 101.84M | 92.13M | 85.04M | 84.41M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 394.65M | 361.11M | 326.76M | 307.89M | 288.38M |
| Operating Income | -350.08M | -313.75M | -276.77M | -261.25M | -248.53M |
| Income Before Tax | -332.13M | -292.56M | -259.99M | -248.82M | -239.48M |
| Income Tax Expenses | -4.06M | -- | -- | -- | -- |
| Earnings from Continuing Operations | -328.07 | -292.56 | -259.99 | -248.82 | -239.48 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -328.07M | -292.56M | -259.99M | -248.82M | -239.48M |
| EBIT | -350.08M | -313.75M | -276.77M | -261.25M | -248.53M |
| EBITDA | -325.68M | -293.69M | -261.30M | -248.53M | -236.78M |
| EPS Basic | -1.57 | -1.47 | -1.38 | -1.38 | -1.37 |
| Normalized Basic EPS | -0.99 | -0.92 | -0.87 | -0.87 | -0.86 |
| EPS Diluted | -1.57 | -1.47 | -1.38 | -1.38 | -1.37 |
| Normalized Diluted EPS | -0.99 | -0.92 | -0.87 | -0.87 | -0.86 |
| Average Basic Shares Outstanding | 830.52M | 793.03M | 752.14M | 722.94M | 702.01M |
| Average Diluted Shares Outstanding | 830.52M | 793.03M | 752.14M | 722.94M | 702.01M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |